PTO/SB/08B (07-05)

Substitute for form 1449/PTO
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

1

Sheet

(use as many sheets as necessary)

of

1

	Approved for use through 07/31/2006.			
Complete if Known				
Application Number	10/517,881			
Filing Date	December 13, 2004			
First Named Inventor	Robin Mark Bannister			
Art Unit	1617			
Examiner Name	Sahar Javanmard			
Attorney Docket Number	GJE.7147			

Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	R1	ANGEL, I. et al., "Litoxetine: a selective 5-HT uptake inhibitor with concomitant 5-HT ₃ -receptor antagonist and antiemetic properties," European Journal of Pharmacology, 1993, Vol. 232, pages 139-145.	
	R2	HOPKINS, "5-HT agonists, antagonists and uptake Inhibitors," Manufacturing Chemist, November 1992, pages 19, 21.	
	R3	OKADA, F. et al., "Prophylactic effect of serotonin uptake inhibitors against motion sickness in Suncus murinus," European Journal of Pharmacology, 1996, Vol. 309, pages 33-35.	
	R4	ROSLAND, J. et al., "The effect of nefopam and its enantiomers on the uptake of 5-hydroxytryptamine, noradrenaline and dopamine in crude rat brain synaptosomal preparations," J. Pharm. Pharmcol. 1990, Vol. 42, pages 437-438.	
	R5		
	R6		
	R7		
	R8		
	R9		
	R10		

Examiner	/Sahar Javanmard/	Date	07/16/0000
Signature	Tourier out annual or	Considered	07/16/2009

*EXAMINER: Initial if inference considered, whether or not claius is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, includuce copy of this form with next communication to applicant.

'Applicant's unique citation designation number (optional). 'Applicant is to place a check mark here if English language Translation is is attached.

This collection of Information is required by 37 CFR 1.98. The information is required to obtain or testian a benefit by the public which is to file (and by the USPTO

This collection of information is required by 37 OFR 1.98. The information is required to obtain or retain a benefit by the public who his to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S. C. 123 and 7 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestors for reducing this burden, should be sent to the Other information C.U.S. Patient and Trademark Office, P.O. Box 1450, Alexandria, VA 2213-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner For Patients, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.